secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001601485-25-000006
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy
--------------------------------------------------------------------------------

- FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.
- Phase 2 AMPLIFY-7P study fully enrolled; interim DFS analysis expected H1 2025.
- Positive Phase 2 results could support rapid advancement into Phase 3 and potential BLA filing.
- ELI-002 is an off-the-shelf monotherapy for mKRAS cancers patients post-chemotherapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/0001601485-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148525000006/angn-20250122.htm
  HTML page:      https://secwatch.observer/filing/0001601485-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer